While combination BRAF-MEK inhibition has become a cornerstone in treating BRAF-mutant melanoma, ongoing research is focused on its optimal role in the adjuvant setting, particularly in comparison with adjuvant immunotherapy. Here, BRAF is linked to melanoma.